53rd Annual Meeting
Swiss Society of Nephrology

Congress Centre Kursaal Interlaken
December 9-10, 2021

COVID certificate mandatory (QR-code)

www.swissnephrology.ch

December 9, 2021
Pflege in der Nephrologie
Soins en Néphrologie
Cure in Nefrologia
Benlysta is now indicated for patients with Lupus Nephritis

Benlysta is indicated
- for the reduction of disease activity in patients aged 5 years and older (infusion solution) or 18 years and older (subcutaneous injection) with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving basic therapy.
- for the treatment of lupus nephritis in adult patients receiving standard therapy.

Benlysta has not been studied in patients with severe, active lupus of the central nervous system.

Benlysta powder for making an infusion solution, solution for subcutaneous injection.

AI: Belimumab.

I: Reduction of disease activity in patients aged 5 years and older (infusion solution) and in patients aged 18 years and older (subcutaneous injection) respectively with active autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy. Treatment of lupus nephritis (LN) in adult patients receiving standard therapy. Belimumab has not been studied in patients with severe active central nervous system lupus.

D: Infusion solution (SLE patients ≥ 5 years): 10 mg/kg on Days 0, 14, 28, and at 4-weeks intervals thereafter. Solution for subcutaneous injection (patients ≥ 18 years): SLE: 200 mg once weekly (independent of body weight). LN: Patients continuing therapy with Benlysta for active LN: 400 mg once weekly for 4 doses, then 200 mg once weekly thereafter. Patients continuing therapy with Benlysta for active LN: 200 mg once weekly.

CI: Hypersensitivity to one of the ingredients.

W/P: Infusion-, injection- and hypersensitivity reactions are possible, which can be severe, or fatal (delay in onset, and recurrence after initial resolution possible). Increased risk of infection possible. Presenting neurological symptoms, possibility of progressive multifocal leukoencephalopathy (PML) should be considered. Increased potential risk for development of malignancies. Before treatment with belimumab, the patient’s risk for depression or suicide must be carefully evaluated and the patient must be monitored accordingly during treatment. The physician must be contacted in the event of new or worsening psychiatric symptoms. Application in combination with other B-cell-targeted therapy was not studied. Live vaccines should not be given for 30 days before or concurrently with Belimumab. No drug interaction studies have been conducted. Evidence of increased clearance of belimumab i.v. when co-administrated with steroids and ACE inhibitors.

P/L: Pregnancy: Belimumab should only be used if the potential benefit to the mother justifies the potential risk to the fetus. If indicated, women of childbearing age should use adequate contraceptive measures while being treated and for at least four months after the last treatment. Safety not verified. In consideration of all aspects it is recommended to consider discontinuing breast-feeding. Lactation: Belimumab is excreted in breast milk. It is recommended that women who are breastfeeding or planning to breastfeed avoid exposure to Belimumab.

P: Pregnancy: Belimumab should only be used if the potential benefit to the mother justifies the potential risk to the fetus. If indicated, women of childbearing age should use adequate contraceptive measures while being treated and for at least four months after the last treatment. Safety not verified. In consideration of all aspects it is recommended to consider discontinuing breast-feeding. Lactation: Belimumab is excreted in breast milk. It is recommended that women who are breastfeeding or planning to breastfeed avoid exposure to Belimumab.

Dear Colleagues,

It is our pleasure to invite you to the 53rd annual meeting of the Swiss Society of Nephrology in Interlaken.

The corona virus pandemic is still a challenge for all of us. Last year’s congress had to be cancelled due to COVID regulations and we very much hope that with ongoing vaccination we will be able to meet in person this year.

The traditional CME course is not part of this year’s annual meeting. It has been organized by the scientific committee and will be held in Aarau on 3rd and 4th of September 2021.

The satellite symposium for nurses will traditionally be held in parallel to the main program on Thursday 9th December 2021.

For the main program two speakers that were planned for last year’s meeting are scheduled to address relevant clinical issues: Prof. Fadi Fakhouri (Lausanne) on the role of complement in glomerular diseases and Prof. Wim van Biesen (Gent) on transition to peritoneal dialysis. Prof. Thomas Fehr (Chur) will talk on SGLT2-inhibitors and their important role in non-diabetic kidney diseases. Dr. Christoph Stein (Heidelberg) will lecture on the microbiome, a field that is gaining more and more importance. The key lecture by Dr. Aitana Lebrand (Genf) will address the use of Artificial Intelligence (AI) in different fields in medicine. Finally, Dr. Urs Stoffel (FMH Olten) will discuss future cost models.

We are very happy to welcome the Young Nephrologists, our next generation of nephrologists and a key to the future of nephrology. This new group will present themselves on Thursday evening.

Come and join us for interesting discussions and networking!

Looking forward to seeing you in Interlaken,

Ann-Kathrin Schwarzkopf
Stephan Segerer
Co-congress presidents SGN-SSN 2021
**General information**

**Congress venue**
Congress Centre Kursaal Interlaken
Strandbadstrasse 44, 3800 Interlaken
www.congress-interlaken.ch

**Registration & congress secretariat**
Meeting-com Congress Organisation
Rue des Pâquis 1 • CP 100 • CH-1033 Cheseaux-sur-Lausanne
Online registration on: www.meeting-com.ch
T +41 21 312 9261 • F +41 21 312 9263 • E info@meeting-com.ch
Onsite registration also possible (onsite fee)

**Registration fees for SGN congress**

<table>
<thead>
<tr>
<th>Member SGN</th>
<th>Early bird fee</th>
<th>Late fee</th>
<th>Onsite fee</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHF 260.00</td>
<td>CHF 300.00</td>
<td>CHF 350.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NON-member SGN</th>
<th>Early bird fee</th>
<th>Late fee</th>
<th>Onsite fee</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHF 380.00</td>
<td>CHF 420.00</td>
<td>CHF 470.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Residents*</th>
<th>Early bird fee</th>
<th>Late fee</th>
<th>Onsite fee</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHF 150.00</td>
<td>CHF 180.00</td>
<td>CHF 210.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Young Swiss Nephrologists (YSN)</th>
<th>Early bird fee</th>
<th>Late fee</th>
<th>Onsite fee</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHF 120.00</td>
<td>CHF 150.00</td>
<td>CHF 180.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Doctoral Students (NCCR)*</th>
<th>Early bird fee</th>
<th>Late fee</th>
<th>Onsite fee</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHF 100.00</td>
<td>CHF 130.00</td>
<td>CHF 160.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Spezialisierte Pflege</th>
<th>Early bird fee</th>
<th>Late fee</th>
<th>Onsite fee</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHF 120.00</td>
<td>CHF 150.00</td>
<td>CHF 180.00</td>
</tr>
</tbody>
</table>

* Confirmation of status for residents/student required to be sent to F 021 312 92 63 or to info@meeting-com.ch.

for the YSN, the Apéro riche is included, but a confirmation of participation is requested (below)

Apéro riche (9.12.21) | CHF 30.00
Apéro riche (9.12.21) | participation YSN (free of charge)

**Included in the registration fees**
Access to the scientific sessions, congress documents, certificate of participation, coffee breaks, light lunches. The Apéro riche on 9.12.21 is not included, and has to be booked separately (see above). Accommodation is not included.

**Payment**
Upon registration you will receive a confirmation by email together with the banking details for the payment. Payment by credit card upon registration is possible.

**Certificate of participation**
The certificate of participation will be sent by secure PDF to all participants after the event.

**Cancellation**
Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CHF 60.00 for administrative costs. Thereafter no refund possible. Any registration made within the “early bird” time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.

**Full virtual event**
In case of full virtual event, the registration costs will remain the same in order to cover the online webplatform and technical costs.

**Industrial exhibition**
An industrial exhibition will take place at the Congress Venue. It will be open throughout the congress. Coffee (breaks) will be offered by exhibitors.

**Hotel booking**
Hotel reservation possible with Interlaken Tourismus on www.interlaken.ch.

**Oral Presentations**
The Scientific Committee will select a number of abstracts which will be presented as oral presentations.
Speaking time: 8 min and 2 min discussion.

**Posters**
The abstracts accepted as poster will be presented in the poster exhibition. The poster needs to be written in English.
The poster format is DIN A0 (portrait – 120 cm height x 85 cm width).
General information

Posterwalk
There will be an organized Posterwalk on Thursday, December 9, 2021, from 18.00 to 19.15 where the highest rated posters in each category will be selected for the Poster Prize Award:
– Basic Science / Genetics / Experimental Nephrology
– Transplantation
– Clinical Nephrology / Hypertension / Mineral / Electrolytes
– Hemodialysis (HD) / Peritoneal Dialysis (PD)
We ask each author to be present near his / her poster during the posterwalk.

SGN/SSN Publication Award
2020: given on Friday, December 10 at 08.45  
2021: given on Friday, December 10 at 11.15

SGN Poster Prize Awards
The four highest rated posters will receive a poster award during the Apéro riche on December 9, 2021 at 19.30.

Young Swiss Nephrology Award
For Young (< 40 yrs) Swiss Nephrologists – given during the Apéro riche on December 9, 2021 at 19.30.

Registration
Authors presenting an accepted paper or poster must register and pay the appropriate registration fee.

Credits
Credit points will be given by the following societies:
SGN-SSN Congress, 9-10.12.21  
SGN-SSN 16 credits  
SGAIM-SSMIG 10 credits

Language
Lectures in English, discussion in German, French or English.

COVID certificate (QR-Code)
Please, take note that due to the pandemic, the Board Committee of the SGN has decided that a COVID certificate (QR-code) will be mandatory for the 53rd Annual Meeting of the Swiss Society of Nephrology.

All participants (attendees, speakers & moderators, committees, industry partners, stand constructors, congress center staff, MC staff, catering staff, etc.) who enter the building of the Kursaal Interlaken during the SGN annual congress must be able to present a valid Swiss COVID certificate, or an EU/non-EU equivalent.

This will be checked at the entrance

The COVID certificate provides documentary evidence of
RECOVERY
must have been no longer than 6 months ago;
VACCINATION
completed for at least 14 days is necessary;
TESTED
a PCR test must not be older than 72 hours, an antigen test not older than 48 hours. After the expiration of the validity period a new test must be submitted on the third day;
EU COUNTRY
a valid EU certificate, this will be accepted;
Non-EU COUNTRY
presentation of a negative result.

Kindly take note that there will be no possibility to being tested at the entrance of the Kursaal.
Program at a glance

### Thursday, December 9, 2021

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Room A</th>
<th>Room B</th>
<th>Room Brünig</th>
</tr>
</thead>
<tbody>
<tr>
<td>From 08.00</td>
<td>Registration</td>
<td>10.00-10.45 State of The Art Lecture</td>
<td></td>
</tr>
<tr>
<td>09.40-09.45</td>
<td>Welcome Address</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45-10.45</td>
<td>State of The Art Lecture</td>
<td>Parallel Symposium Sponsored by Otsuka</td>
<td>Parallel Symposium Sponsored by Sanofi Genzyme</td>
</tr>
<tr>
<td>10.15-11.15</td>
<td>Coffee break – Visit of the exhibition – Poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15-12.00</td>
<td>Parallel Symposium Sponsored by Otsuka</td>
<td>Parallel Symposium Sponsored by Sanofi Genzyme</td>
<td></td>
</tr>
<tr>
<td>12.00-12.15</td>
<td>Short break</td>
<td>11.15-12.45 PflegeSymposium</td>
<td></td>
</tr>
<tr>
<td>12.15-13.15</td>
<td>Oral Parallel Presentations Basic Science/Genetics/Experimental Nephrology &amp; NCCR Kidney.CH</td>
<td>Oral Parallel Presentations Transplantation</td>
<td></td>
</tr>
<tr>
<td>13.15-14.00</td>
<td>Lunch snacks in the exhibition – Poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.45</td>
<td>Parallel Symposium Sponsored by Fresenius Medical Care</td>
<td>Parallel Symposium Sponsored by Vifor</td>
<td>14.00-15.30 PflegeSymposium</td>
</tr>
<tr>
<td>14.45-15.30</td>
<td>State of The Art Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Coffee break – Visit of the exhibition – Poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-16.45</td>
<td>State of The Art Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.45-17.00</td>
<td>Young Swiss Nephrology Session (YSN)</td>
<td>Swiss Stone Cohort</td>
<td>Swiss Dialysis Registry</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00-19.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30</td>
<td>WELCOME RECEPTION – APÉRO RICHE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Friday December 10, 2021

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Room A</th>
<th>Room B</th>
</tr>
</thead>
<tbody>
<tr>
<td>From 07.00</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>07.45-08.45</td>
<td>General Assembly SGN-SSN</td>
<td></td>
</tr>
<tr>
<td>08.45-09.00</td>
<td>Publication Award 2020</td>
<td></td>
</tr>
<tr>
<td>09.00-09.45</td>
<td>State of the Art Lecture</td>
<td></td>
</tr>
<tr>
<td>09.45-10.00</td>
<td>Short break</td>
<td></td>
</tr>
<tr>
<td>10.00-10.45</td>
<td>Parallel Symposium Sponsored by Bayer</td>
<td>Parallel Symposium Sponsored by GSK</td>
</tr>
<tr>
<td>10.45-11.15</td>
<td>Coffee break – Visit of the exhibition – Poster viewing</td>
<td></td>
</tr>
<tr>
<td>11.15-11.30</td>
<td>Publication Award 2021</td>
<td></td>
</tr>
<tr>
<td>11.30-12.15</td>
<td>State of the Art Lecture</td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td>Short break</td>
<td></td>
</tr>
<tr>
<td>12.30-13.15</td>
<td>Parallel Symposium Sponsored by AstraZeneca</td>
<td>Parallel Symposium Sponsored by Kyowa Kirin</td>
</tr>
<tr>
<td>13.15-14.00</td>
<td>Lunch snacks – Visit of the exhibition – Poster viewing</td>
<td></td>
</tr>
<tr>
<td>14.00-14.50</td>
<td>Oral Parallel Presentations Clinical Nephrology/Hypertension/Mineral/Electrolytes</td>
<td>Oral Parallel Presentations Hemodialysis (HD)/Peritoneal Dialysis (PD)</td>
</tr>
<tr>
<td>14.50-15.00</td>
<td>State of The Art Lecture</td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td>Coffee Break – Visit of the exhibition – Poster viewing</td>
<td></td>
</tr>
<tr>
<td>15.30-17.00</td>
<td>Hot Topics / Update 2021</td>
<td></td>
</tr>
<tr>
<td>17.00</td>
<td>Farewell</td>
<td></td>
</tr>
</tbody>
</table>
Thursday, December 9

**Special Satellite Symposium**

*Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia*

Sprache: Deutsch, Französisch und Italienisch

(Slides und Fragen: in den anderen zwei Sprachen)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-10.15</td>
<td><strong>Begrüssung</strong> &lt;br&gt; <em>Claudia Studer, Prisca Coduri, Ursula Dietrich</em></td>
<td></td>
</tr>
<tr>
<td>10.15-10.45</td>
<td><strong>Dialyseabbruch / Lebensqualität bis zum Tod</strong> &lt;br&gt; <em>Tanja von Arx, Aarau</em></td>
<td></td>
</tr>
<tr>
<td>10.45-11.15</td>
<td><strong>Coffee break – Visit of the exhibition – Poster viewing</strong></td>
<td><em>Exhibition space</em></td>
</tr>
<tr>
<td>11.15-11.45</td>
<td><strong>Sexualität, Kinderwunsch und Schwangerschaft an der Dialyse</strong> &lt;br&gt; <em>Samantha Chase, Winterthur</em></td>
<td></td>
</tr>
<tr>
<td>11.45-12.15</td>
<td><strong>Il paziente anziano in dialisi: identificazione dei bisogni di cura per una presa in carico globale</strong> &lt;br&gt; <em>Francesca Tartaglia, Bellinzona</em></td>
<td></td>
</tr>
<tr>
<td>12.15-12.45</td>
<td><strong>La qualité de la relation infirmière-patient en hémodialyse: résultats prometteurs du projet exp.care</strong> &lt;br&gt; <em>Philippe Delmas, Matteo Antonini, Tanja Bellier-Teichmann, Lausanne</em></td>
<td></td>
</tr>
<tr>
<td>13.15-14.00</td>
<td><strong>Lunch snacks – Visit of the exhibition – Poster viewing</strong></td>
<td><em>Exhibition space</em></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td><strong>Patientenschulung Peritonealdialyse kritisch betrachtet – Eine Fallanalyse</strong></td>
<td><em>Ilianka Lees, Bern</em></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td><strong>L’organizzazione del Servizio Infermieristico di Emodialisi dell’Ospedale Regionale di Locarno «La Carità» durante la pandemia COVID-19</strong></td>
<td><em>Nadine Poletti Cacio, Locarno</em></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Ê tre en deuxième ligne (Equipe de recherche ProH-COVID)</strong> &lt;br&gt; <em>Matteo Antonini, Margaux Perriraz, Philippe Delmas, Claudia Ortoleva Bucher, Tanja Bellier-Teichmann, Isabelle Peytremann Bridevaux, Ingrid Gilles</em></td>
<td><em>Lausanne</em></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td><strong>Coffee break – Visit of the exhibition – Poster viewing</strong></td>
<td><em>Exhibition space</em></td>
</tr>
<tr>
<td>16.00-17.15</td>
<td><strong>Interprofessionelle Zusammenarbeit im Setting der Hämodialyse - ein Vorzeigebeispiel für gelungene Interprofessionalität zwischen Pflegenden und Ärzten?</strong></td>
<td><em>Christina Venzin, Davos</em></td>
</tr>
<tr>
<td>17.15</td>
<td><strong>Verabschiedung</strong> &lt;br&gt; <em>Claudia Studer, Prisca Coduri, Ursula Dietrich</em></td>
<td></td>
</tr>
</tbody>
</table>
## Thursday, December 9

### From 8.00
Registration

### 09.40-09.45
**Opening of the 53rd Annual Meeting of the Swiss Society of Nephrology & Welcome Address**

- Ann-Kathrin Schwarzkopf, Bern
- Stephan Segerer, Aarau

### 09.45-10.15
**STATE OF THE ART LECTURES**

- **Chairs**: Harald Seeger, Zurich; Stephan Segerer, Aarau
- **SGLT-2 Inhibition in kidney disease and beyond**
  - Thomas Fehr, Chur

### 10.15-10.45
**Transition in renal replacement therapy**

- Wim van Biesen, Gent (BE)

### 10.45-11.15
Coffee break – Visit of the exhibition – Poster viewing

### 11.15-12.00
**PARALLEL SYMPOSIUM**

- **Sponsored by Otsuka**
  - *(How) can we reduce corticosteroid exposure in Lupus Nephritis?*
    - **Chair**: Uyen Huynh-Do, Bern
    - **Speaker**: Andreas Kistler, Frauenfeld

- **PARALLEL SYMPOSIUM**
  - **Sponsored by Sanofi Genzyme**
    - **New Insights for Nephrologists on Diagnosis and Therapy:**
      - **Tracking down aTTP and Fabry disease**
        - **Chair**: Fadi Fakhouri, Lausanne
      - **Fabry disease: Phenotype, genotype and their impact on treatment decisions**
        - Albina Nowak, Zurich
      - **Acquired thrombotic thrombocytopenic purpura – from evidence to clinical practice**
        - Mario Bargetzi, Aarau

### 12.00-12.15
Short break

---

### Thursday, December 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.15-13.15</td>
<td>6 ORAL PARALLEL PRESENTATIONS Room A</td>
</tr>
<tr>
<td><strong>Room A</strong></td>
<td><strong>Basic Science/Genetics/Experimental Nephrology &amp; NCCR Kidney.CH</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs</strong>: Eric Feraille, Geneva; Grégoire Wuerzner, Lausanne</td>
</tr>
<tr>
<td><strong>OC 01</strong></td>
<td><em>(12.15-12.25)</em> Interim analysis of a Phase 2 dose ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy – Matthias Meier, Basel</td>
</tr>
<tr>
<td><strong>OC 02</strong></td>
<td><em>(12.25-12.35)</em> 24p3 receptor (24p3R) knockout reduces kidney fibrosis and inflammation during proteinuric kidney disease* – Thomas Verissimo, Geneva</td>
</tr>
<tr>
<td><strong>OC 03</strong></td>
<td><em>(12.35-12.45)</em> Fetuin-A attenuates fibrotic remodeling and improves renal function in a mouse model of ischemia reperfusion injury – Stefan Rudloff, Bern</td>
</tr>
<tr>
<td><strong>OC 04</strong></td>
<td><em>(12.45-12.55)</em> Claudin-4 is involved in chloride retention of nephrotic syndrome (NCCR project) * – Ali Sassi, Geneva</td>
</tr>
<tr>
<td><strong>OC 05</strong></td>
<td><em>(12.55-13.05)</em> Urinary cystathionine protects from calcium oxalate nephropathy – Dusan Harmacek, Lausanne</td>
</tr>
<tr>
<td><strong>OC 06</strong></td>
<td><em>(13.05-13.15)</em> Glomerular proteomic profiling of kidney biopsies with hypertensive nephropathy reveals a signature of disease progression – Hans-Peter Marti, Bergen, Norway</td>
</tr>
</tbody>
</table>

* YSN paper
Thursday, December 9

12.15-13.15  5 ORAL PARALLEL PRESENTATIONS  
Room B

12.15-12.25  OC 07 Transplantation
Successful tolerance induction by combined kidney and hematopoietic stem cell transplantation – Kerstin Hübel, Zurich

12.25-12.35  OC 08 Transplantation
Functionaldual nanoparticles remove donor-specific antibodies (DSA) from patient blood. Preliminary data of an ex vivo feasibility and proof-of-principle study* – Francis Lauener, Zurich

12.35-12.45  OC 09 Transplantation

12.45-12.55  OC 10 Transplantation
Comparing methods for donor-derived cell-free dna quantification in plasma and urine from kidney and liver transplant recipients – Nicholas Küng, Bern

12.55-13.05  OC 11 Transplantation
Outcome of patients transplanted for glomerulonephritis in the Swiss kidney transplant cohort* – Mathieu Halfon, Lausanne

*YSN paper

13.15-14.00 Lunch break – Visit of the exhibition – Poster viewing  
Exhibition space

14.00-14.45 PARALLEL SYMPOSIUM  
Room A

14.00-14.45  PARALLEL SYMPOSIUM
Sponsored by FRESENIUS MEDICAL CARE
Membrane Innovation from Bench to Bedside
Chair: Patrice M. Ambühl, Prof., Head Department Medical Institutes, Head Institute of Nephrology, Stadtpital Zurich
How can membrane innovation improve outcomes?
Bernard Canaud, Prof., Senior Medical Scientist, Global Medical Office EMEA Fresenius Medical Care France / Germany
Nano-controlled membrane surface architecture leads to reduced hemoreactivity and increased toxin removal
James Kennedy, Dr, Global Director for New Product Development Fresenius Medical Care USA

14.00-14.45  PARALLEL SYMPOSIUM
Sponsored by VIFOR
Silent killers in CKD: how can prevention revert tendency?
Chair: Felix Burkhalter, KS Baselland
Optimal management of CKD patients with RAAS inhibitors through long-term K+ control: case discussions
Nora Schwotzer, CHUV, Lausanne
Early management of secondary hyperparathyroidism in non-dialysis CKD
Spyridon Arampatzis, Nierenzentrum Bern and Lindenhofspital Dialyse Bern

14.45-15.30 STATE OF THE ART LECTURE  
Room A

14.45-15.30  STATE OF THE ART LECTURE
Chairs: Michael Dickenmann, Basel; Ann-Kathrin Schwarzkopf, Bern
AI: Nephrology goes digital
Altana Lebrand, SIB Genf

15.30-16.00 Coffee break – Visit of the exhibition – Poster viewing  
Exhibition space

16.00-16.45 "STATE OF THE ART LECTURE" roundtable  
Room A

16.00-16.45  "STATE OF THE ART LECTURE"
Chairs: Dominik Uehlinger, Bern; Stephan Segerer, Aarau
The nephrologists dilemma
Urs Stoffel, FMH Olten
Silent killers in CKD: how can prevention revert tendency?

SGN/SSN Congress – Kursaal Interlaken
Thursday, December 9th, 2021, 14.00-14.45 h

CHAIR
Dr. med. Felix Burkhalter, Leiter Nephrologie, KS Baselland

PART I Optimal management of CKD patients with RAAS inhibitors through long-term K⁺ control: case discussions
Dr. méd. Nora Schwotzer (CHUV, Lausanne)

PART II Early management of secondary hyperparathyroidism in non-dialysis CKD
Prof. Dr. med. Spyridon Arampatzis (Nierenzentrum Bern and Lindenhofspital Dialyse Bern)

Request the presentation slides
sgncongress@viforpharma.com or simply scan here:

This satellite symposium is sponsored by Vifor AG, Route de Moncor 10, 1752 Villars-sur-Glâne, 53rd Annual Meeting of Swiss Society of Nephrology, Interlaken, December 9th-10th, 2021
### Friday, December 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>From 07.00</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07.45-08.45</td>
<td><strong>SGN GENERAL ASSEMBLY</strong></td>
<td><strong>A</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 08.45-09.00   | **SGN/SSN PUBLICATION AWARD 2020**                                    | **A** | Sponsored by Otsuka  
Chairs: Rudolf Wüthrich, Zurich; Johannes Loffing, Zurich  
*Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1–associated membranous nephropathy*  
George Haddad, 1, 2 Johan M. Lorenzen, 1, 2 Hong Ma, 3 Noortje de Haan, 4 Harald Seeger, 1, 2 Christelle Zaghrrini, 5 Simone Brandt, 6 Malte Kölling, 1 Urs Wegmann, 7 Bence Kiss, 7 Gábor Pál, 7 Péter Gál, 8 Rudolf P. Wüthrich, 1, 2 Manfred Wuhrer, 4 Laurence H. Beck, 3 David J. Salant, 3 Gérard Lambeau, 5 and Andreas D. Kistler 1, 2, 9  
*J Clin Invest.* 2021;131(5):e140453  
https://doi.org/10.1172/JCI140453. |
| 09.00-09.45   | **STATE OF THE ART LECTURE**                                          | **A** | Chairs: Sophie de Seigneux, Geneva; Maja Klein Lüthi, Burgdorf  
**Microbiome: Does it matter**  
Christoph Stein-Thöringer, Heidelberg (D)  
*Complement in kidney disease: where do we stand*  
Fadi Fakhouri, Lausanne |
| 09.45-10.00   | Short break                                                           |       |                                                                      |
| 10.00-10.45   | **PARALLEL SYMPOSIUM**                                                | **A** | Sponsored by BAYER  
*Treatment perspectives for patients with chronic kidney disease and type-2 diabetes*  
Harald Seeger, Zurich; Grégoire Wurzner, Lausanne |
| 10.00-10.45   | **PARALLEL SYMPOSIUM**                                                | **B** | Sponsored by GSK  
*Treatment of lupus nephritis*  
Chair: Carlo Chizzolini, Geneva  
Speakers: Uyen Huynh-Do, Bern; Denis Comte, Lausanne |
| 10.45-11.15   | Coffee break – Visit of the exhibition – Poster viewing              |       | Exhibition space                                                      |
| 11.15-11.30   | **SGN/SSN PUBLICATION AWARD 2021**                                    | **A** | Sponsored by Otsuka  
Chairs: Rudolf Wüthrich, Zurich; Johannes Loffing, Zurich  
*Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1–associated membranous nephropathy*  
George Haddad, 1, 2 Johan M. Lorenzen, 1, 2 Hong Ma, 3 Noortje de Haan, 4 Harald Seeger, 1, 2 Christelle Zaghrrini, 5 Simone Brandt, 6 Malte Kölling, 1 Urs Wegmann, 7 Bence Kiss, 7 Gábor Pál, 7 Péter Gál, 8 Rudolf P. Wüthrich, 1, 2 Manfred Wuhrer, 4 Laurence H. Beck, 3 David J. Salant, 3 Gérard Lambeau, 5 and Andreas D. Kistler 1, 2, 9  
*J Clin Invest.* 2021;131(5):e140453  
https://doi.org/10.1172/JCI140453. |
| 11.30-12.15   | **STATE OF THE ART LECTURE**                                          | **A** | Chairs: Pierre-Yves Martin, Geneva; Menno Pruijm, Lausanne  
*Complement in kidney disease: where do we stand*  
Fadi Fakhouri, Lausanne |
| 12.15-12.30   | Short break                                                           |       |                                                                      |
| 12.30-13.15   | **PARALLEL SYMPOSIUM**                                                | **A** | Sponsored by AstraZeneca  
*Taking the lead in CKD: DAPA-CKD implications for Nephrologists*  
Roger Lehmann, Zurich; Sophie de Seigneux, Geneva |
| 12.30-13.15   | **PARALLEL SYMPOSIUM**                                                | **B** | Sponsored by KYOWA KIRIN  
*New perspectives in the treatment of X-linked hypophosphatemia*  
Chair: Dagmar L’Allemand, Kinderspital St.Gallen  
Speakers: Daniel Fuster, Marco Janner; Inselspital Bern |
| 13.15-14.00   | Lunch break – Visit of the exhibition – Poster Viewing              |       | Exhibition space                                                      |
Friday, December 10

14.00-15.00  6 ORAL PARALLEL PRESENTATIONS

Room A

**CLINICAL NEPHROLOGY**

Chairs: Olivier Bonny, Lausanne; Isabelle Binet, St.Gallen

OC 12 (14.00-14.10)
Uromodulin, Blood Pressure and Chronic Kidney Disease: Assessing Causality Using Mendelian Randomization – Bélen Ponte, Geneva

OC 13 (14.10-14.20)
Cardiovascular outcomes associated with achieved haemoglobin level and preliminary rate of rise of haemoglobin in pooled phase 3 studies of roxadustat in non–dialysis-dependent patients with anaemia – Nada Dimkovic, Belgrade, Serbia

OC 14 (14.20-14.30)
Urinary tetrahydroaldosterone is associated with circulating FGF23 in kidney stone formers – Matthias Moor, Bern

OC 15 (14.30-14.40)
Characteristics and outcomes of pregnancy-triggered atypical hemolytic-uremic syndrome (aHUS): global aHUS registry analysis – Fadi Fakhouri, Lausanne

OC 16 (14.40-14.50)
Predictors of bone mineral density in kidney stone formers – Nasser A. Dhayat, Bern

OC 17 (14.50-15.00)
Hypertensive patients have a decreased microperfusion response during a cold pressure test compared to healthy participants – Marielle Hendriks-Balk, Lausanne

Friday, December 10

14.00-15.00  5 ORAL PARALLEL PRESENTATIONS

Room B

**DIALYSIS**

Chairs: Hans-Rudolf Räz, Baden; Stefan Farese, Solothurn

OC 18 (14.00-14.10)
Seroconversion, cellular response and persistence of immunogenicity following COVID-19 mRNA vaccination in a cohort of swiss hemodialysis patients – Stefan Farese, Solothurn

OC 19 (14.10-14.20)
COVID-19 pandemic in dialysis patients: the Swiss experience – Rebecca Guidotti, Zurich

OC 20 (14.20-14.30)
Peritoneal dialysis (PD)-related peritonitis rate and microbiology spectrum: a ten-year single center cohort-study – Raphael Korach, St.Gallen

OC 21 (14.30-14.40)
Management and outcomes of patients on maintenance dialysis during the first and second wave of the COVID-19 pandemic in Geneva, Switzerland – Ido Zamberg, Geneva

OC 22 (14.40-14.50)
Computational nephrology part 1: hemodialysis* – Edward Pivin, Sion

*YSN paper
**Friday, December 10**

15.00-15.30  Coffee break – Visit of the exhibition – Poster viewing

**15.30-17.00  HOT TOPICS / UPDATE 2021**

**Room A**

**Chairs:** Ann-Kathrin Schwarzkopf, Bern; Stephan Segerer, Aarau

15.30-16.00  **CKD**

Sophie de Seigneux, Geneva

16.00-16.30  **Transplantation**

Caroline Wehrmeier, Basel

16.30-17.00  **Kidney Immune Study: Immune response to vaccines in dialysis patients**

Olivier Giannini, Mendrisio

17.00  **Farewell**

Ann-Kathrin Schwarzkopf, Bern; Stephan Segerer, Aarau
Bewährte Leistung, die ankommt.
In ganz neuer Form.

Magnesium-Diasporal® 100 CitraCaps
Die einzige geschmacksneutrale, kassenzulässige Kapsel mit 100% Magnesium-Citrat für hervorragende Bioverfügbarkeit.1
Gut geeignet für geschmacks-empfindliche Personen, Schwangere oder Langzeitanwender.

• geschmacksneutral1
• kassenzulässig1
• nur 1x täglich 3 Kapseln1

1) Fachinformation Magnesium-Diasporal® 100 CitraCaps unter www.swissmedicinfo.ch
2) Spezialitätenliste des BAG unter www.spezialitaetenliste.ch
3) Walker AF et al. Mg citrate found more bioavailable than other Mg preparations in a randomised, double blind study. Mag Resarch 2003;16:183-191
4) Gedruckt Fachinformation: Magnesium-Diasporal® 100 CitraCaps, Kapseln / Magnesium-Diasporal® 300, Granulat / Magnesium-Diasporal® 300 zuckerfrei, Granulat / Wirkstoff: Magnesium und Magnesium-citras; 100 mg Magnesium = 12.4 mmol pro Sachet.
Plan of exhibition

Exhibitors

Company | Booth
--- | ---
MCM MEDSYS | 1
DOETSCH GRETER | 2
SYNLAB | 3
SALMON PHARMA | 4
BRACCO | 5
KYOWA KIRIN | 6
GSK | 7
ASTRAZENCA | 8
BAYER | 9
DIALYSEREGISTER | 10
ASTELLAS | 11
ASTELLAS | 12
ASTELLAS | 13
BAXTER | 14
FONI MEDICAL | 15
CANON MEDICAL | 16
CHIESI | 17
OTSUKA | 18
AMGEN | 19
NEOVII | 20
AMICUS | 21
B.BRAUN | 22
SANOFI-AVENTIS | 23
LABORATORIUM DR. G. BICHSEL | 24
VIFOR | 25
FRESENIUS MEDICAL CARE | 26
THERAMED | 27
ALEXION | 28
YSN | 29
VNPS | 30
MILTENYI BIOTECH | 31
AIRG | 32
DEVATIS | 33
ALNYLAM | 34
Association

Association pour l’Information et la Recherche sur les maladies rénales Génétiques (AIRG)

Verband Nierenpatienten Schweiz (VNPS)

Young Swiss Nephrology

Kind thanks to the City of Interlaken

Advertisement

AstraZeneca
Bayer (Schweiz) AG
GlaxoSmithKline SA
Otsuka Pharmaceutical (Switzerland) GmbH
sanofi-aventis (Switzerland) AG
Vifor SA

Sponsored symposia in alphabetical order

AstraZeneca AG
PARALLEL SYMPOSIUM
Friday, December 10, 2021 – 12.30-13.15 / Room A

Bayer (Schweiz) AG
PARALLEL SYMPOSIUM
Friday, December 10, 2021 – 10.00-10.45 / Room A

Fresenius Medical Care
PARALLEL SYMPOSIUM
Thursday, December 9, 2021 – 14.00-14.45 / Room A

GlaxoSmithKline SA
PARALLEL SYMPOSIUM
Friday, December 10, 2021 – 10.00-10.45 / Room B

Kyowa Kirin Sàrl
PARALLEL SYMPOSIUM
Friday, December 10, 2021 – 12.30-13.15 / Room B

Otsuka Pharmaceutical (Switzerland) GmbH
PARALLEL SYMPOSIUM
Thursday, December 9, 2021 – 11.15-12.00 / Room A

Sanofi-Aventis (Switzerland) AG
PARALLEL SYMPOSIUM
Thursday, December 9, 2021 – 11.15-12.00 / Room B

Vifor SA
PARALLEL SYMPOSIUM
Thursday, December 9, 2021 – 14.00-14.45 / Room B
Save the date: SGN-SSN congress 2022

We would like to invite you to the

54th Annual Meeting of the Swiss Society of Nephrology SGN-SSN
on December 8-9, 2022 – Congress Centre Kursaal Interlaken

Please save the dates of December 8-9, 2022!
We look forward to welcoming you in Interlaken next year!
Fighting complex diseases with groundbreaking therapies.

*aTTP = acquired Thrombotic Thrombocytopenic Purpura; MAHA = Microangiopathic Haemolytic Anaemia.

* In conjunction with plasma exchange (PEX) and immunosuppression.
† Severe thrombocytopenia (typically < 30 x 10^9/L).


When you diagnose aTTP, start Cablivi®

Cablivi® can protect against microthrombi from the start of therapy giving you the crucial time to stabilise and treat your patient

Cablivi 10 mg powder and solvent for the preparation of a solution for injection:

AI: Caplacizumab 10 mg. I: Treatment of adults and adolescents of 12 years and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura aTTP in conjunction with plasmapheresis and immunosuppression.

D: Initial dose 10 mg i.v. prior to plasmapheresis; subsequent doses 10 mg s.c. after completion of every plasmapheresis, then 10 mg s.c. daily for up to 30 days after finishing the daily plasmapheresis treatment. A forgotten dose can be made up within the next 12 hours.

Contraindication: Oversensitivity. Cautionary measures: No data available for children and adolescents or on patients with severe liver dysfunction. An adjustment of the dose or particular cautionary measures may be necessary with older patients. In the case of active clinically relevant bleeding, treatment should be discontinued. Patients with coagulopathy must be closely monitored. Discontinue therapy at least 7 days before planned operations or dental interventions and inform the surgeon. In emergency operations the use of a von Willebrand factor concentrate can be considered.

Interaction: platelet aggregation inhibitors, anticoagulants, low molecular weight heparin: due to potentially raised risk of haemorrhage, careful consideration and close monitoring.

Side effects: Epistaxis, headaches, bleeding, tiredness, urticaria, fever.

P: 1 vial with 10 mg powder and 1 pre-filled syringe with solvent.

Med. class: B. MAH: sanofi-aventis (suisse) sa, 1214 Vernier. Updated: March 2021. For further information please see the prescribing information at www.swissmedicinfo.ch.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected new or serious adverse reactions. See the “Undesirable effects” section for advice on the reporting of adverse reactions.

sanofi-aventis (suisse) sa – Route de Montfleury 3 - 1214 Vernier